These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 4024663)

  • 1. Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant.
    Pontani RB; Vadlamani NL; Misra AL
    Xenobiotica; 1985 Apr; 15(4):287-97. PubMed ID: 4024663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biliary excretion, metabolism and enterohepatic circulation of buprenorphine.
    Brewster D; Humphrey MJ; McLeavy MA
    Xenobiotica; 1981 Mar; 11(3):189-96. PubMed ID: 7293215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metabolism and excretion of buprenorphine in humans.
    Cone EJ; Gorodetzky CW; Yousefnejad D; Buchwald WF; Johnson RE
    Drug Metab Dispos; 1984; 12(5):577-81. PubMed ID: 6149907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A long-acting buprenorphine delivery system.
    Pontani RB; Misra AL
    Pharmacol Biochem Behav; 1983 Mar; 18(3):471-4. PubMed ID: 6836002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buprenorphine: high-affinity binding to dorsal spinal cord.
    Villiger JW; Taylor KM
    J Neurochem; 1982 Jun; 38(6):1771-3. PubMed ID: 6281389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine : characteristics of binding sites in the rat central nervous system.
    Villiger JW; Taylor KM
    Life Sci; 1981 Dec; 29(26):2699-708. PubMed ID: 6276633
    [No Abstract]   [Full Text] [Related]  

  • 7. The peripheral narcotic antagonist N-allyl levallorphan-bromide (CM 32191) selectively prevents morphine antipropulsive action and buprenorphine in-vivo binding in the rat intestine.
    Bianchi G; Fiocchi R; Peracchia F; Petrillo P; Tavani A; Manara L
    J Pharm Pharmacol; 1984 May; 36(5):326-30. PubMed ID: 6145770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The systemic bioavailability of buprenorphine by various routes of administration.
    Brewster D; Humphrey MJ; Mcleavy MA
    J Pharm Pharmacol; 1981 Aug; 33(8):500-6. PubMed ID: 6115924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation in vivo of the receptor constants of morphine in naive and morphine-tolerant rats.
    Porreca F; Cowan A; Raffa RB; Tallarida RJ
    Life Sci; 1982 Nov 15-22; 31(20-21):2355-8. PubMed ID: 6298527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine: differential interaction with opiate receptor subtypes in vivo.
    Sadée W; Rosenbaum JS; Herz A
    J Pharmacol Exp Ther; 1982 Oct; 223(1):157-62. PubMed ID: 6288917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of buprenorphine to opiate receptors. Regulation by guanyl nucleotides and metal ions.
    Villiger JW
    Neuropharmacology; 1984 Mar; 23(3):373-5. PubMed ID: 6328350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical actions of fentanyl and buprenorphine. The significance of receptor binding.
    Boas RA; Villiger JW
    Br J Anaesth; 1985 Feb; 57(2):192-6. PubMed ID: 2982388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine kinetics.
    Bullingham RE; McQuay HJ; Moore A; Bennett MR
    Clin Pharmacol Ther; 1980 Nov; 28(5):667-72. PubMed ID: 7438685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiological disposition and biotransformation of (3H) cocaine in acutely and chronically treated rats.
    Nayak PK; Misra AL; Mulé SJ
    J Pharmacol Exp Ther; 1976 Mar; 196(3):556-69. PubMed ID: 1263111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions.
    Dum JE; Herz A
    Br J Pharmacol; 1981 Nov; 74(3):627-33. PubMed ID: 6271322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversibility of opioid receptor occupancy of buprenorphine in vivo.
    Englberger W; Kögel B; Friderichs E; Strassburger W; Germann T
    Eur J Pharmacol; 2006 Mar; 534(1-3):95-102. PubMed ID: 16490191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy.
    Heel RC; Brogden RN; Speight TM; Avery GS
    Drugs; 1979 Feb; 17(2):81-110. PubMed ID: 378645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sublingual buprenorphine used postoperatively: clinical observations and preliminary pharmacokinetic analysis.
    Bullingham RE; McQuay HJ; Dwyer D; Allen MC; Moore RA
    Br J Clin Pharmacol; 1981 Aug; 12(2):117-22. PubMed ID: 7306425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic modelling of intravenous, intramuscular and subcutaneous buprenorphine in conscious cats.
    Steagall PV; Pelligand L; Giordano T; Auberger C; Sear JW; Luna SP; Taylor PM
    Vet Anaesth Analg; 2013 Jan; 40(1):83-95. PubMed ID: 22998333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo opiate receptor binding of oripavines to mu, delta and kappa sites in rat brain as determined by an ex vivo labeling method.
    Richards ML; Sadée W
    Eur J Pharmacol; 1985 Aug; 114(3):343-53. PubMed ID: 2998812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.